Abstract:Programmed cell death-1 (PD-1) is an immunosuppressive receptor expressed on T cells upon activation. Once interacting with its ligands, programmed death ligand-1 (PD-L1), the PD-1:PD-L pathway curbs T cell activation and thereby serves as a natural protection mechanism against autoimmunity. However, this pathway has been hijacked by cancer cells in order to evade the immune system. In fact, PD-L1 is commonly overexpressed on the surface of tumor cells as well as other cells in the tumor microenvironment, such as myeloid-derived suppressor cells. This interface has already been recognized as an effective target for cancer therapy. Blocking the PD-1:PD-L axis would unleash T cells from suppression to maintain their effector function against tumor cells. At least two anti-PD-1 and three anti-PD-L1 blocking antibodies have been approved for human cancer immunotherapy. However, these drugs are only successful in a small number of cancers. Therefore, developing inhibitors that block this axis more effectively and have a wider scale of impact is necessary. We used a molecular docking model and performed virtual chemical library screening to identify small molecule inhibitors of PD-1 and PD-L1 interactions. To this end, we have identified 175 PD-L1 small molecule inhibitors. Functional assays were established with the 4T1 murine breast cancer cell line and a tumor-specific murine T cell line in the presence or absence of the PD-L1 small molecule inhibitors to test if these small molecule PD-L1 inhibitors can increase T cell killing of tumor cells. Cell viability assays were also done to test the toxicity of these inhibitors on tumor cells in the absence of T cells. From these studies, we have identified ten novel PD-L1 small molecule inhibitors that can significantly increase the lytic activity of the tumor-specific cytotoxic T lymphocytes (CTLs) to kill 4T1 tumor cells. These ten PD-L1 small molecule inhibitors show little to no cytotoxicity to 4T1 tumor cells in the absence of the antigen-specific T cells, suggesting that these small molecule inhibitors themselves are not cytotoxic, and therefore are potentially safe as therapeutic agents. These proof of concept studies indicate that these small molecule inhibitors are potentially potent agents for blocking PD-1 and PD-L1 interaction in cancer immunotherapy. Citation Format: Priscilla S. Redd, Chunwan Lu, David Ostrov, Iryna Lebedyeva, Kebin Liu. Interference of PD-1 and PD-L1 interaction with small-molecule inhibitors enhances the efficacy of tumor-specific CTLs [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1679.

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy

Peptide Blockers of PD-1-PD-L1 Interaction Reinvigorate PD-1-Suppressed T Cells and Curb Tumor Growth in Mice

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

Abstract 1679: Interference of PD-1 and PD-L1 Interaction with Small-Molecule Inhibitors Enhances the Efficacy of Tumor-Specific CTLs

Abstract 3851: Novel Small-Molecule Inhibitor of PD1/PDL1 Pathway Demonstrated Single Agent and Drug Combo Effectiveness in Cancer Immunotherapy

In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-l/PD-L1 interaction

Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway

Pd-1-Targeted Discovery Of Peptide Inhibitors By Virtual Screening, Molecular Dynamics Simulation, And Surface Plasmon Resonance

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway

Abstract 2039: Cellular characterization of small molecule PD-L1 inhibitors reveal their novel mechanisms of action

Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy

Preclinical anti-tumor activity of small-molecule oral PD-L1 checkpoint inhibitors.

Peptide blocking of PD-1/PD-L1 interaction for cancer immunotherapy.

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Small Molecules As PD-1/PD-L1 Pathway Modulators for Cancer Immunotherapy

Rational Development of Molecularly Imprinted Nanoparticles for Blocking PD-1/PD-L1 Axis

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity

Develop a PD-1-blockade Peptide to Reinvigorate T-cell Activity and Inhibit Tumor Progress.

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy